Logo image of CRVS

CORVUS PHARMACEUTICALS INC (CRVS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRVS - US2210151005 - Common Stock

7.52 USD
-0.28 (-3.59%)
Last: 12/23/2025, 12:25:07 PM
Fundamental Rating

3

CRVS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. CRVS has a great financial health rating, but its profitability evaluates not so good. CRVS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRVS has reported negative net income.
CRVS had a negative operating cash flow in the past year.
In the past 5 years CRVS always reported negative net income.
In the past 5 years CRVS always reported negative operating cash flow.
CRVS Yearly Net Income VS EBIT VS OCF VS FCFCRVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CRVS has a Return On Assets of -18.73%. This is in the better half of the industry: CRVS outperforms 76.98% of its industry peers.
CRVS has a Return On Equity of -21.01%. This is amongst the best in the industry. CRVS outperforms 82.45% of its industry peers.
Industry RankSector Rank
ROA -18.73%
ROE -21.01%
ROIC N/A
ROA(3y)-70.1%
ROA(5y)-51.36%
ROE(3y)-111.59%
ROE(5y)-77.52%
ROIC(3y)N/A
ROIC(5y)N/A
CRVS Yearly ROA, ROE, ROICCRVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRVS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVS Yearly Profit, Operating, Gross MarginsCRVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

CRVS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CRVS has been increased compared to 5 years ago.
There is no outstanding debt for CRVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRVS Yearly Shares OutstandingCRVS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRVS Yearly Total Debt VS Total AssetsCRVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

An Altman-Z score of 32.47 indicates that CRVS is not in any danger for bankruptcy at the moment.
The Altman-Z score of CRVS (32.47) is better than 93.96% of its industry peers.
There is no outstanding debt for CRVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 32.47
ROIC/WACCN/A
WACCN/A
CRVS Yearly LT Debt VS Equity VS FCFCRVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

CRVS has a Current Ratio of 8.29. This indicates that CRVS is financially healthy and has no problem in meeting its short term obligations.
CRVS has a better Current ratio (8.29) than 75.28% of its industry peers.
CRVS has a Quick Ratio of 8.29. This indicates that CRVS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CRVS (8.29) is better than 75.28% of its industry peers.
Industry RankSector Rank
Current Ratio 8.29
Quick Ratio 8.29
CRVS Yearly Current Assets VS Current LiabilitesCRVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

CRVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.89%, which is quite impressive.
EPS 1Y (TTM)78.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 17.11% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y70.34%
EPS Next 2Y17.35%
EPS Next 3Y8.75%
EPS Next 5Y17.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRVS Yearly Revenue VS EstimatesCRVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M
CRVS Yearly EPS VS EstimatesCRVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVS Price Earnings VS Forward Price EarningsCRVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVS Per share dataCRVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.35%
EPS Next 3Y8.75%

More info and screens

0

5. Dividend

5.1 Amount

CRVS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CORVUS PHARMACEUTICALS INC

NASDAQ:CRVS (12/23/2025, 12:25:07 PM)

7.52

-0.28 (-3.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)03-23 2026-03-23/amc
Inst Owners38.98%
Inst Owner Change-1.57%
Ins Owners3.95%
Ins Owner Change0%
Market Cap561.59M
Revenue(TTM)N/A
Net Income(TTM)-15.07M
Analysts86.15
Price Target15.64 (107.98%)
Short Float %16.88%
Short Ratio8.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.85%
Min EPS beat(2)11.83%
Max EPS beat(2)29.87%
EPS beat(4)3
Avg EPS beat(4)66.86%
Min EPS beat(4)-47.55%
Max EPS beat(4)273.3%
EPS beat(8)5
Avg EPS beat(8)-10.56%
EPS beat(12)8
Avg EPS beat(12)-6.23%
EPS beat(16)9
Avg EPS beat(16)-12.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.22%
PT rev (3m)3.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.97%
EPS NY rev (1m)-1.77%
EPS NY rev (3m)33.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.83
P/tB 7.83
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0
BVpS0.96
TBVpS0.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.73%
ROE -21.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.1%
ROA(5y)-51.36%
ROE(3y)-111.59%
ROE(5y)-77.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.29
Quick Ratio 8.29
Altman-Z 32.47
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y70.34%
EPS Next 2Y17.35%
EPS Next 3Y8.75%
EPS Next 5Y17.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-54.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.79%
EBIT Next 3YN/A
EBIT Next 5Y43.26%
FCF growth 1Y-22.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.9%
OCF growth 3YN/A
OCF growth 5YN/A

CORVUS PHARMACEUTICALS INC / CRVS FAQ

What is the fundamental rating for CRVS stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRVS.


What is the valuation status for CRVS stock?

ChartMill assigns a valuation rating of 0 / 10 to CORVUS PHARMACEUTICALS INC (CRVS). This can be considered as Overvalued.


Can you provide the profitability details for CORVUS PHARMACEUTICALS INC?

CORVUS PHARMACEUTICALS INC (CRVS) has a profitability rating of 1 / 10.


What is the financial health of CORVUS PHARMACEUTICALS INC (CRVS) stock?

The financial health rating of CORVUS PHARMACEUTICALS INC (CRVS) is 8 / 10.


Can you provide the expected EPS growth for CRVS stock?

The Earnings per Share (EPS) of CORVUS PHARMACEUTICALS INC (CRVS) is expected to grow by 70.34% in the next year.